Recursion Pharmaceuticals (RXRX) closed at $3.01 in the latest trading session, marking a +1.69% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw ...

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $2.97, marking a -2.62% move from the previous day. This move lagged the S&P 500's daily loss of 1.52%. On the other hand, the ...

AM ET / 6:00 AM MT / 1:00 PM BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices.

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...